Medicare Will Limit Coverage of Biogen's Alzheimer's Drug to Those in Clinical TrialsBarrons • 04/08/22
BIIB FINAL DEADLINE: Hagens Berman, National Trial Attorneys, Alerts Biogen Inc. (BIIB) Investors to Tomorrow's Lead Plaintiff DeadlineNewsfile Corp • 04/07/22
BIIB 8-DAY INVESTOR DEADLINE: Hagens Berman, National Trial Attorneys, Reminds Biogen Inc. (BIIB) Investors of April 8th Lead Plaintiff Deadline, Encourages Investors with Losses to Contact Firm's AttorneysNewsfile Corp • 04/05/22
New Data at AAN 2022 Highlight Real-World Evidence from Biogen's MS Portfolio and Emerging Research on Disease ProgressionGlobeNewsWire • 04/04/22
Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to FDAGlobeNewsWire • 03/30/22
Biogen (BIIB), Ionis to End Early-Stage ALS Candidate DevelopmentZacks Investment Research • 03/29/22
Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral SclerosisPRNewsWire • 03/28/22
BIOGEN INC. (NASDAQ: BIIB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Biogen Inc. (NASDAQ: BIIB)PRNewsWire • 03/23/22
Biogen Announces Peer-Reviewed Publication of ADUHELM® Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer's DiseaseGlobeNewsWire • 03/16/22
Biogen Inc. Company News: Berger Montague Investigates Securities Fraud Allegations Against Biogen, Inc. (BIIB); Lead Plaintiff Deadline is April 8, 2022Newsfile Corp • 03/16/22